

ACADIA PHARMACEUTICALS INC
Form 4
September 04, 2007

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Hacksell Uli

2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ACAD]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

(Last) (First) (Middle)
3911 SORRENTO VALLEY BOULEVARD
(Street)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2007

Director 10% Owner
 Officer (give title below) Other (specify below)
CEO

SAN DIEGO, CA 92121

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
| | | | | Code V Amount (A) or (D) Price | | | |
| Common Stock | 09/04/2007 | | S ⁽¹⁾ | 900 D \$ 15.19 | 87,016 | I | By Family Trust |
| Common Stock | 09/04/2007 | | S ⁽¹⁾ | 200 D \$ 15.16 | 86,816 | I | By Family Trust |
| Common Stock | 09/04/2007 | | S ⁽¹⁾ | 2,400 D \$ 15.15 | 84,416 | I | By Family Trust |
| Common Stock | 09/04/2007 | | S ⁽¹⁾ | 372 D \$ 15.03 | 84,044 | I | By Family Trust |
| Common Stock | 09/04/2007 | | S ⁽¹⁾ | 400 D \$ 15.01 | 83,644 | I | By Family Trust |

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

| | | | | | | | | |
|--------------|------------|------------------------|-------|---|----------|--------|---|-----------------|
| Common Stock | 09/04/2007 | <u>S⁽¹⁾</u> | 4,728 | D | \$ 15 | 78,916 | I | By Family Trust |
| Common Stock | 09/04/2007 | <u>S⁽¹⁾</u> | 400 | D | \$ 14.83 | 78,516 | I | By Family Trust |
| Common Stock | 09/04/2007 | <u>S⁽¹⁾</u> | 100 | D | \$ 14.82 | 78,416 | I | By Family Trust |
| Common Stock | 09/04/2007 | <u>S⁽¹⁾</u> | 100 | D | \$ 14.81 | 78,316 | I | By Family Trust |
| Common Stock | 09/04/2007 | <u>S⁽¹⁾</u> | 2,400 | D | \$ 14.8 | 75,916 | I | By Family Trust |
| Common Stock | 09/04/2007 | <u>S⁽¹⁾</u> | 200 | D | \$ 14.47 | 75,716 | I | By Family Trust |
| Common Stock | 09/04/2007 | <u>S⁽¹⁾</u> | 800 | D | \$ 14.46 | 74,916 | I | By Family Trust |
| Common Stock | 09/04/2007 | <u>S⁽¹⁾</u> | 1,000 | D | \$ 14.45 | 73,916 | I | By Family Trust |
| Common Stock | | | | | | 8,300 | D | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 6) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
| | | | | | | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| | | | | | | Code | V | (A) | (D) |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| Hacksell Uli 3911 SORRENTO VALLEY BOULEVARD SAN DIEGO, CA 92121 | X | | CEO | |

Signatures

/s/ Kirk V. Crawford,
Attorney-in-Fact

09/04/2007

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales reported in this Form 4 were effected pursuant to an existing sales plan established under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The plan provides for the non-discretionary periodic sales of stock pursuant to predetermined trading parameters that do not permit Dr. Hacksell to exercise any subsequent influence over how, when or whether to effect trades under the plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.